These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12114656)

  • 1. Octreotide Effect on Growth Hormone and Somatostatin Subtype 2 Receptor mRNAs of the Human Pituitary Somatotroph Adenomas.
    Stefaneanu L; Kovacs K; Thapar K; Horvath E; Melmed S; Greenman Y
    Endocr Pathol; 2000; 11(1):41-48. PubMed ID: 12114656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
    Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study.
    Asa SL; Felix I; Kovacs K; Ramyar L
    Endocr Pathol; 1990 Dec; 1(4):228-235. PubMed ID: 32357614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.
    Ezzat S; Kontogeorgos G; Redelmeier DA; Horvath E; Harris AG; Kovacs K
    Eur J Endocrinol; 1995 Dec; 133(6):686-90. PubMed ID: 8548053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro.
    Kontogeorgos G; Asa SL; Kovacs K; Smyth HS; Singer W
    Acta Endocrinol (Copenh); 1993 Dec; 129(6):565-72. PubMed ID: 7509101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
    Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
    J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.
    Li J; Stefaneanu L; Kovacs K; Horvath E; Smyth HS
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(3):193-201. PubMed ID: 8493775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological effects of octreotide on growth hormone-producing pituitary adenomas.
    Ezzat S; Horvath E; Harris AG; Kovacs K
    J Clin Endocrinol Metab; 1994 Jul; 79(1):113-8. PubMed ID: 8027215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone and prolactin gene expression in human densely and sparsely granulated somatotroph adenomas by in situ hybridization with digoxigenin-labeled probes.
    Yamada S; Takahashi M; Hara M; Sano T; Aiba T; Shishiba Y; Suzuki T; Asa SL
    Diagn Mol Pathol; 1994 Mar; 3(1):46-52. PubMed ID: 8162255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas.
    Kato M; Inoshita N; Sugiyama T; Tani Y; Shichiri M; Sano T; Yamada S; Hirata Y
    Endocr J; 2012; 59(3):221-8. PubMed ID: 22200580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
    J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.
    Barlier A; Pellegrini-Bouiller I; Gunz G; Zamora AJ; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2759-65. PubMed ID: 10443675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
    J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.
    George SR; Kovacs K; Asa SL; Horvath E; Cross EG; Burrow GN
    Clin Endocrinol (Oxf); 1987 Apr; 26(4):395-405. PubMed ID: 2888549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial.
    Thapar K; Kovacs KT; Stefaneanu L; Scheithauer BW; Horvath E; Lloyd RV; Li J; Laws ER
    Mayo Clin Proc; 1997 Oct; 72(10):893-900. PubMed ID: 9379690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.